← All Painreform LTD filings

Painreform LTD 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
PRFX
Painreform LTD
20-F: PRF Technologies Shifts Focus After Clinical Setback, Eyes AI Solar Growth
PRF Technologies reports significant losses and a going concern warning, pivoting its drug development to OcuRing-K while expanding its DeepSolar AI analytics business.
NASDAQ
PRFX
Painreform LTD
20-F: PainReform Ltd. Reports 2024 Annual Results; Highlights Strategic Shift with DeepSolar Acquisition
PainReform Ltd. files its 20-F, detailing 2024 financials and outlining a strategic move into AI-driven solar analytics with the acquisition of DeepSolar.
NASDAQ
PRFX
Painreform LTD
20-F: PainReform Ltd. Files 20-F Report, Details Financials and Ongoing Clinical Trials
PainReform Ltd. released its 20-F filing, outlining its financial status, ongoing clinical trials for PRF-110, and potential risks.